{"product_id":"the-maudsley-prescribing-guidelines-in-psychiatry-paperback-softback-9781394238767","title":"The Maudsley Prescribing Guidelines in Psychiatry (Paperback \/ softback) 9781394238767","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eThe Maudsley Prescribing Guidelines in Psychiatry\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cfont size=\"4\"\u003eDavid M. Taylor (Author), Thomas R. E. Barnes (Author), Allan H. Young (Author)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9781394238767, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003ePaperback \/ softback, published 17 April 2025\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e1024 pages\u003cbr\u003e24.4 x 17 x 4.1 cm, 1.724 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003e\u003cp\u003e\u003cb\u003eThe most up-to-date edition of the gold-standard handbook on the safe and effective prescribing of psychotropic agents\u003c\/b\u003e \u003c\/p\u003e\n\u003cp\u003ePrescribing medications that treat mental illness is a challenging but essential component of clinical practice. Successful treatment outcomes require careful drug choice and dosage, and other considerations can also have an important impact on patient experiences and long-term care. \u003c\/p\u003e\n\u003cp\u003eIn the newly revised fifteenth edition of \u003ci\u003eThe Maudsley Prescribing Guidelines in Psychiatry,\u003c\/i\u003e you will find up-to-date and authoritative guidance on prescribing psychotropic medications to patients. It is an indispensable evidence-based handbook that will continue to serve a new generation of clinicians and trainees. \u003c\/p\u003e\n\u003cp\u003eThe book includes analyses of all psychotropic drugs currently used in the United States, the United Kingdom, Canada, Australia, New Zealand, and Japan. It also contains detailed discussions of common and uncommon adverse effects, the ramifications of switching medications, special patient groups, and other clinically relevant subjects. A fully updated reference list closes out each section, as well. \u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eThe Maudsley Prescribing Guidelines in Psychiatry\u003c\/i\u003e is perfect for trainees seeking essential and accurate information on the rational, safe, and effective use of medications for patients with mental illness. Practising clinicians will also benefit from the included guidance on complex issues that might arise less frequently.\u003c\/p\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003ePreface xi\u003cbr\u003eAcknowledgements xiii\u003cbr\u003eContributors' conflict of interest xv\u003cbr\u003eList of abbreviations xvii\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 1 Schizophrenia and related psychoses 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAntipsychotic Drugs 1\u003cbr\u003eGeneral introduction 1\u003cbr\u003eGeneral principles of prescribing 7\u003cbr\u003eAntipsychotics – minimum effective doses 8\u003cbr\u003eQuick reference for licensed maximum doses 11\u003cbr\u003eEquivalent doses 14\u003cbr\u003eHigh- dose antipsychotic medication: prescribing and monitoring 17\u003cbr\u003eCombined antipsychotics (antipsychotic polypharmacy) 22\u003cbr\u003eAntipsychotic prophylaxis 28\u003cbr\u003eNegative symptoms 34\u003cbr\u003eMonitoring 40\u003cbr\u003eRelative adverse effects – a rough guide 43\u003cbr\u003eTreatment algorithms for schizophrenia 45\u003cbr\u003eFirst- generation antipsychotics – place in therapy 49\u003cbr\u003eNICE guidelines for the treatment of schizophrenia 52\u003cbr\u003eAntipsychotic response – to increase the dose, to switch, to add or just wait – what is the right move? 55\u003cbr\u003eAcutely disturbed or violent behaviour 62\u003cbr\u003eAntipsychotic depots\/long- acting injections 74\u003cbr\u003eDepot antipsychotics – summary of pharmacokinetics 81\u003cbr\u003eManagement of patients on long- term treatment with long- acting injectable antipsychotic medication 83\u003cbr\u003eAripiprazole long- acting injection 85\u003cbr\u003eOlanzapine long- acting injection 90\u003cbr\u003ePaliperidone palmitate long- acting injection 93\u003cbr\u003eRisperidone long- acting injection 99\u003cbr\u003ePenfluridol weekly 106\u003cbr\u003eElectroconvulsive therapy and psychosis 108\u003cbr\u003eOmega- 3 fatty acid (fish oils) in schizophrenia 111\u003cbr\u003eAlternative routes of administration 115\u003cbr\u003eStopping antipsychotics 119\u003cbr\u003eAntipsychotic Adverse Effects 126\u003cbr\u003eExtrapyramidal symptoms 126\u003cbr\u003eAkathisia 131\u003cbr\u003eTreatment of tardive dyskinesia 135\u003cbr\u003eAntipsychotic- induced weight gain 141\u003cbr\u003eTreatment of antipsychotic- induced weight gain 144\u003cbr\u003eNeuroleptic malignant syndrome 150\u003cbr\u003eCatatonia 154\u003cbr\u003eECG changes – QT prolongation 161\u003cbr\u003eEffects of antipsychotic medications on plasma lipids 169\u003cbr\u003eDiabetes and impaired glucose tolerance 174\u003cbr\u003eBlood pressure changes with antipsychotics 182\u003cbr\u003eAntipsychotic- associated hyponatraemia 186\u003cbr\u003eHyperprolactinaemia 190\u003cbr\u003eSexual dysfunction and antipsychotics 195\u003cbr\u003ePneumonia 204\u003cbr\u003eSwitching antipsychotics 207\u003cbr\u003eVenous thromboembolism 211\u003cbr\u003eRefractory Schizophrenia and Clozapine 214\u003cbr\u003eClozapine initiation schedules 214\u003cbr\u003eIntramuscular clozapine 219\u003cbr\u003eOptimising clozapine treatment 220\u003cbr\u003eAlternatives to clozapine 226\u003cbr\u003eRestarting clozapine after a break in treatment 234\u003cbr\u003eInitiation of clozapine in the community 236\u003cbr\u003eClozapine Adverse Effects 241\u003cbr\u003eClozapine: common adverse effects 241\u003cbr\u003eClozapine: uncommon or unusual adverse effects 245\u003cbr\u003eClozapine: serious haematological adverse effects 251\u003cbr\u003eClozapine: serious cardiovascular adverse effects 253\u003cbr\u003eClozapine- induced hypersalivation 258\u003cbr\u003eClozapine- induced gastrointestinal hypomotility 263\u003cbr\u003eClozapine, neutropenia and lithium 267\u003cbr\u003eClozapine and chemotherapy 273\u003cbr\u003eGenetic testing for clozapine treatment 275\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 2 Bipolar disorder 279\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eLithium 279\u003cbr\u003eValproate 289\u003cbr\u003eCarbamazepine 295\u003cbr\u003eAntipsychotic drugs in bipolar disorder 300\u003cbr\u003eAntipsychotic long- acting injections in bipolar disorder 305\u003cbr\u003ePhysical monitoring for people with bipolar disorder 308\u003cbr\u003eTreatment of acute mania or hypomania 310\u003cbr\u003eRapid- cycling bipolar affective disorder 316\u003cbr\u003eBipolar depression 319\u003cbr\u003eProphylaxis in bipolar disorder 326\u003cbr\u003eStopping lithium and mood stabilisers 331\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 3 Depression and anxiety disorders 335\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction to depression 335\u003cbr\u003eAntidepressants – general overview 337\u003cbr\u003eRecognised minimum effective doses of antidepressants 342\u003cbr\u003eDrug treatment of depression 344\u003cbr\u003eManagement of treatment-resistant depression – commonly used treatments 348\u003cbr\u003eManagement of treatment-resistant depression – other well-supported treatments 351\u003cbr\u003eTreatment-resistant depression – other reported treatments 353\u003cbr\u003eKetamine 357\u003cbr\u003ePsychotic depression 362\u003cbr\u003eSwitching antidepressants 366\u003cbr\u003eAntidepressant withdrawal symptoms 373\u003cbr\u003eStopping antidepressants 378\u003cbr\u003eElectroconvulsive therapy and psychotropic drugs 384\u003cbr\u003ePsychostimulants in depression 388\u003cbr\u003ePost- stroke depression 393\u003cbr\u003eAntidepressant prophylaxis 397\u003cbr\u003eDrug interactions with antidepressants 401\u003cbr\u003eCardiac effects of antidepressants – summary 406\u003cbr\u003eAntidepressant- induced arrhythmia 411\u003cbr\u003eAntidepressant- induced hyponatraemia 416\u003cbr\u003eAntidepressants and hyperprolactinaemia 420\u003cbr\u003eAntidepressants and diabetes mellitus 423\u003cbr\u003eAntidepressants and sexual dysfunction 426\u003cbr\u003eSSRIs and bleeding 432\u003cbr\u003eSt John's wort 440\u003cbr\u003eAntidepressants: relative adverse effects – a rough guide 444\u003cbr\u003eAnxiety spectrum disorders 446\u003cbr\u003eBenzodiazepines in the treatment of psychiatric disorders 460\u003cbr\u003eBenzodiazepines, z-drugs and gabapentinoids: dependence, withdrawal effects and discontinuation 464\u003cbr\u003eBenzodiazepines and disinhibition 471\u003cbr\u003ePremenstrual syndrome 474\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 4 Addictions and substance misuse 477\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 477\u003cbr\u003eAlcohol dependence 479\u003cbr\u003eOpioid dependence 498\u003cbr\u003eNicotine and smoking cessation 523\u003cbr\u003eStimulant use disorder (SUD) 532\u003cbr\u003eGHB and GBL dependence 537\u003cbr\u003eBenzodiazepine misuse 540\u003cbr\u003eDrug- induced excited state 543\u003cbr\u003eInteractions between illicit drugs and prescribed psychotropic drugs 545\u003cbr\u003eDrugs of misuse – a summary 549\u003cbr\u003eSubstance misuse in pregnancy 554\u003cbr\u003eGambling disorder 560\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 5 Prescribing in children and adolescents 561\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003ePrinciples of prescribing practice in childhood and adolescence 561\u003cbr\u003eDepression in children and adolescents 566\u003cbr\u003eBipolar disorder in children and adolescents 573\u003cbr\u003ePsychosis in children and adolescents 580\u003cbr\u003eAnxiety disorders in children and adolescents 582\u003cbr\u003eObsessive compulsive disorder (OCD) and body dysmorphic disorder (BDD) in children and adolescents 587\u003cbr\u003ePost- traumatic stress disorder (PTSD) in children and adolescents 595\u003cbr\u003eAttention deficit hyperactivity disorder (ADHD) in children and adolescents 597\u003cbr\u003eAutism spectrum disorder (ASD) in children and adolescents 605\u003cbr\u003eTics and Tourette’s syndrome in children and adolescents 614\u003cbr\u003eMelatonin in the treatment of insomnia in children and adolescents 620\u003cbr\u003eRapid tranquillisation (RT) in children and adolescents 623\u003cbr\u003eDoses of commonly used psychotropic drugs in children and adolescents 626\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 6 Prescribing in older people 627\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eGeneral principles in prescribing in older adults 627\u003cbr\u003eDementia 630\u003cbr\u003eSafer prescribing for physical conditions in dementia 654\u003cbr\u003eManagement of behavioural and psychological symptoms of dementia (BPSD) 667\u003cbr\u003eManagement of inappropriate sexual behaviour in older adults 680\u003cbr\u003eDepression in older adults 688\u003cbr\u003eCovert administration of medicines within food and drink 694\u003cbr\u003eA guide to medication doses of commonly used psychotropics in older adults 700\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 7 Prescribing in pregnancy and breastfeeding 713\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eDrug choice in pregnancy 713\u003cbr\u003eDrug choice in breastfeeding 734\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 8 Prescribing in hepatic and renal impairment 753\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eHepatic impairment 753\u003cbr\u003eRenal impairment 766\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 9 Drug treatment of other psychiatric conditions 787\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eBorderline personality disorder (BPD) 787\u003cbr\u003eEating disorders 792\u003cbr\u003eAttention deficit hyperactivity disorder (ADHD) in adults 798\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 10 Drug treatment of psychiatric symptoms occurring in the context of other conditions 803\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003ePrescribing in human immunodeficiency virus (HIV) 803\u003cbr\u003eEpilepsy 811\u003cbr\u003e22q11.2 deletion syndrome 820\u003cbr\u003eLearning disabilities 824\u003cbr\u003eHuntington’s disease 830\u003cbr\u003eMultiple sclerosis 835\u003cbr\u003eParkinson’s disease 840\u003cbr\u003eAtrial fibrillation 845\u003cbr\u003eBariatric surgery 849\u003cbr\u003eMenopause 857\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 11 Pharmacokinetics 865\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003ePlasma level monitoring of psychotropic drugs 865\u003cbr\u003eInterpreting postmortem blood concentrations 879\u003cbr\u003eActing on clozapine plasma concentration results 881\u003cbr\u003ePsychotropic drugs and cytochrome (CYP) function 883\u003cbr\u003eSmoking and psychotropic drugs 892\u003cbr\u003eDrug interactions with alcohol 895\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 12 Other substances 901\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eCaffeine 901\u003cbr\u003eNicotine 908\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 13 Psychotropic drugs in special conditions 913\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003ePsychotropics in overdose 913\u003cbr\u003eDriving and psychotropic medicines 921\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 14 Prescribing psychotropics 927\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eWorking towards adherence 927\u003cbr\u003eRestarting psychotropic medications after a period of non- compliance 937\u003cbr\u003eRelational aspects of prescribing practice 939\u003cbr\u003ePrescribing drugs outside their licensed indications (‘off- label’ prescribing) 945\u003cbr\u003eThe Mental Health Act in England and Wales 949\u003cbr\u003eSite of administration of intramuscular injections 954\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 15 Miscellany 959\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eBiochemical and haematological effects of psychotropics 959\u003cbr\u003eSummary of psychiatric adverse effects of non- psychotropics 969\u003c\/p\u003e \u003cp\u003eIndex 975\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Other branches of medicine [\u003ca title=\"See our other books on Other branches of medicine\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Other%20branches%20of%20medicine%20%5BMM%5D%22\"\u003eMM\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Brand New","offer_id":52164941873432,"sku":"9781394238767","price":50.35,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9781394238767.jpg?v=1781082250","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/the-maudsley-prescribing-guidelines-in-psychiatry-paperback-softback-9781394238767","provider":"Freshly Printed Books","version":"1.0","type":"link"}